{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:02:46Z","timestamp":1791918166778,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche - Medical Writing Support"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with diabetic macular oedema (DMO)\/neovascular age-related macular degeneration (nAMD) treated with faricimab in the UK. We present results from FARWIDE-DMO for eyes with 12 months of follow-up after faricimab initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FARWIDE-DMO includes patients with diagnosis of DMO who received \u22651 intravitreal faricimab injection after May 2022 in the diagnosed eye(s) at 1 of 35 UK National Health Service sites. All eyes had \u226512 months of follow-up after faricimab initiation as of July 2024. Treatment-na\u00efve (TN) eyes had no prior anti-VEGF therapy or steroid implant. Previously treated (PT) eyes switched to faricimab. Baseline characteristics, visual acuity (VA) outcomes and treatment patterns were evaluated. Intraocular inflammation (IOI) and presumed infectious endophthalmitis (PIE) incidences were pooled for all nAMD\/DMO eyes with any follow-up duration. Analyses are descriptive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2147 eyes (1564 patients) were included (TN, 32.1%; PT, 67.9%). For TN eyes, mean (standard deviation [SD]) VA at baseline and 12 months were 63.9 (15.2) and 68.4 (16.3) Early Treatment Diabetic Retinopathy Study letters, respectively. VA remained stable in PT eyes. TN eyes received a mean (SD) of 4.5 (1.0) faricimab injections in months 1\u20136 and 1.9 (1.2) injections in months 7\u201312. PT eyes received 4.5 (1.2) injections in months 1\u20136 and 2.4 (1.3) in months 7\u201312. IOI and PIE rates were consistent with faricimab phase 3 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These 1-year data support real-world effectiveness, durability and safety of faricimab in DMO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04059-8","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:12:14Z","timestamp":1761207134000},"page":"3350-3358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":false,"given":"Tunde","family":"Peto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Talks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-6942","authenticated-orcid":false,"given":"Gabriella","family":"de Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-4067","authenticated-orcid":false,"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0213-6253","authenticated-orcid":false,"given":"Richard P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0811-3969","authenticated-orcid":false,"given":"Rhianon","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kiire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8748-5299","authenticated-orcid":false,"given":"Melanie","family":"Dodds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalee","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"4059_CR1","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s00417-024-06558-y","volume":"262","author":"S Nakao","year":"2024","unstructured":"Nakao S, Kusuhara S, Murakami T. Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology. Graefes Arch Clin Exp Ophthalmol. 2024;262:3749\u201359.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4059_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"4059_CR3","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247\u201354.","journal-title":"Ophthalmology"},{"key":"4059_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes. Br J Ophthalmol. 2021;105:216\u201321.","journal-title":"Br J Ophthalmol"},{"key":"4059_CR5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/OPTH.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346.","journal-title":"Clin Ophthalmol"},{"key":"4059_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14746","volume":"39","author":"T Peto","year":"2022","unstructured":"Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabet Med. 2022;39:e14746.","journal-title":"Diabet Med"},{"key":"4059_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, Gentile B, Chi GC, Mirt M, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"key":"4059_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ. Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol Ther. 2023;12:809\u201326.","journal-title":"Ophthalmol Ther"},{"key":"4059_CR9","volume":"2023","author":"G Virgili","year":"2023","unstructured":"Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2023;2023:CD007419.","journal-title":"Cochrane Database Syst Rev"},{"key":"4059_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0401-y","volume":"17","author":"F Ziemssen","year":"2017","unstructured":"Ziemssen F, Feltgen N, Holz FG, Guthoff R, Ringwald A, Bertelmann T, et al. Demographics of patients receiving intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmol. 2017;17:7.","journal-title":"BMC Ophthalmol"},{"key":"4059_CR11","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating diabetic macular oedema - technology appraisal guidance. 2022. https:\/\/www.nice.org.uk\/guidance\/ta799\/resources\/faricimab-for-treating-diabetic-macular-oedema-pdf-82611625700293."},{"key":"4059_CR12","unstructured":"European Medicines Agency. Vabysmo EPAR. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vabysmo."},{"key":"4059_CR13","unstructured":"Food and Drug Administration. Vabysmo prescribing information. 2024. https:\/\/www.gene.com\/download\/pdf\/vabysmo_prescribing.pdf."},{"key":"4059_CR14","unstructured":"European Medicines Agency. Vabysmo Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vabysmo-epar-product-information_en.pdf."},{"key":"4059_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"4059_CR16","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion. 2024. https:\/\/www.nice.org.uk\/guidance\/ta1004\/resources\/faricimab-for-treating-visual-impairment-caused-by-macular-oedema-after-retinal-vein-occlusion-pdf-2973528213295813."},{"key":"4059_CR17","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating wet age-related macular degeneration. 2024. https:\/\/www.nice.org.uk\/guidance\/ta800\/resources\/faricimab-for-treating-wet-agerelated-macular-degeneration-pdf-82613243170501."},{"key":"4059_CR18","doi-asserted-by":"publisher","first-page":"1192464","DOI":"10.3389\/fncel.2023.1192464","volume":"17","author":"J Canonica","year":"2023","unstructured":"Canonica J, Foxton R, Garrido MG, Lin CM, Uhles S, Shanmugam S, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion. Front Cell Neurosci. 2023;17:1192464.","journal-title":"Front Cell Neurosci"},{"key":"4059_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2023","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2023;131:708\u201323.","journal-title":"Ophthalmology"},{"key":"4059_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitr. 2024;10:5.","journal-title":"Int J Retin Vitr"},{"key":"4059_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"NQX Quah","year":"2024","unstructured":"Quah NQX, Javed KMAA, Arbi L, Hanumunthadu D. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024;18:1479\u201390.","journal-title":"Clin Ophthalmol"},{"key":"4059_CR22","first-page":"6259","volume":"65","author":"H Khan","year":"2024","unstructured":"Khan H, Khan H, Aziz AA, Gahn G, Barakat MR, Corradetti G, et al. The real-world efficacy and safety of faricimab in diabetic macular edema: the TAHOE study. Investig Ophthalmol Vis Sci. 2024;65:6259.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4059_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/medicina59040665","volume":"59","author":"S Kusuhara","year":"2023","unstructured":"Kusuhara S, Kishimoto-Kishi M, Matsumiya W, Miki A, Imai H, Nakamura M. Short-term outcomes of intravitreal faricimab injection for diabetic macular edema. Medicina. 2023;59:665.","journal-title":"Medicina"},{"key":"4059_CR24","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OPTH.S381503","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol. 2022;16:2797\u2013801.","journal-title":"Clin Ophthalmol"},{"key":"4059_CR25","first-page":"2699","volume":"64","author":"D Tabano","year":"2023","unstructured":"Tabano D, Borkar DS, Garmo V, Shaia JK, Kuo B, Myers R, et al. FARETINA-DME- early treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: an IRIS RegistryTM analysis. Investig Ophthalmol Vis Sci. 2023;64:2699.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4059_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30:1046\u201350.","journal-title":"Retina"},{"key":"4059_CR27","unstructured":"Community Care\/Social Care Ageing and Disability\/Dementia and Disabilities\/Cost Centre 18278. Certificate of vision impairment: explanatory notes for consultant ophthalmologists and hospital eye clinic staff in England. 2016. https:\/\/assets.publishing.service.gov.uk\/media\/5a7f88a9ed915d74e33f7065\/Explanatory_Notes.pdf."},{"key":"4059_CR28","unstructured":"Norridge CFE, Gruszka-Goh MH, McKibbin M, Henry P, Donachie J. National Ophthalmology Database Audit: the first report of age-related macular degeneration audit (AMD). 2023. https:\/\/nodaudit.org.uk\/sites\/default\/files\/2023-02\/NOD%20AMD%20Audit%20Full%20Annual%20Report%202023_0.pdf."},{"key":"4059_CR29","doi-asserted-by":"crossref","unstructured":"Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD, et al. Intraocular inflammation associated with faricimab therapy: one-year real world outcomes. Retina. 2025;45:827\u201332.","DOI":"10.1097\/IAE.0000000000004394"},{"key":"4059_CR30","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s40123-024-00999-8","volume":"13","author":"T Li","year":"2024","unstructured":"Li T, Berdunov V, Hamilton R, Rojas YG, B\u00fchrer C, Cox O, et al. Economic assessment in resource-constrained systems: individual-level simulation model in wet age-related macular degeneration and diabetic macular oedema. Ophthalmol Ther. 2024;13:2577\u201397.","journal-title":"Ophthalmol Ther"},{"key":"4059_CR31","first-page":"4353","volume":"65","author":"S Sood","year":"2024","unstructured":"Sood S, Vail D, Berkowitz S, Zhang C, Coovadia Z, Budhu U, et al. Costs of novel 8 mg aflibercept and faricimab compared to 2mg aflibercept and bevacizumab for neovascular age-related macular degeneration and diabetic macular edema at 2 years. Investig Ophthalmol Vis Sci. 2024;65:4353.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4059_CR32","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jval.2023.03.381","volume":"26","author":"C B\u00fchrer","year":"2023","unstructured":"B\u00fchrer C, Diles D. EE76 budget Impact of faricimab in patients with diabetic macular edema and neovascular age related degeneration in Canada. Value Health. 2023;26:S73.","journal-title":"Value Health"},{"key":"4059_CR33","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/j.jval.2023.09.826","volume":"26","author":"D Klabukova","year":"2023","unstructured":"Klabukova D, Krysanova V, Krysanov I, Ermakova V, Kolosov Y, Makarova E. EE561 The comparative pharmacoeconomic analysis of using different anti-VEGF drugs for diabetic macular edema therapy in Russia. Value Health. 2023;26:S160\u2013S1.","journal-title":"Value Health"},{"key":"4059_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.oret.2023.12.001","volume":"8","author":"B Momenaei","year":"2024","unstructured":"Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, et al. Rates of ocular adverse events after intravitreal faricimab injections. Ophthalmol Retina. 2024;8:311\u20133.","journal-title":"Ophthalmol Retin"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04059-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:39:02Z","timestamp":1764599942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04059-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":34,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4059"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04059-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TP: Advisory Board: Alimera, Allergan, Apellis, Bayer, Novartis, Optos, Roche, ZEISS; Consultancy: Boehringer Ingelheim, Roche; Investigator-Initiated Grant: Boehringer Ingelheim, Novartis; Speaker: Alimera, Allergan, Bayer, Heidelberg Engineering, Novartis, Optos, ZEISS. Editorial role: Eye journal. IP: Advisory Board\/Consulting\/Honoraria\/Travel Expenses: Allergen, Apellis, Bayer, Boehringer Ingelheim, Novartis, Roche. JT: Advisory Board: Bayer, Roche; Consultancy: Bayer, Roche; Speaker: Alimera, Bayer, Heidelberg Engineering, Roche; Travel Support: Bayer, Heidelberg Engineering, Roche; Research: Bayer, Boehringer Ingelheim, Janssen, Roche. GdS: Advisory Board: AbbVie, Apellis, Astellas, Bayer, Novartis, Roche, Teva; Consultancy: Boehringer Ingelheim, Roche; Speaker\/Travel Support: AbbVie, Bayer, Heidelberg Engineering, Novartis, Roche; Editorial role: Eye journal. PJP: Speaker Fees: Bayer, Roche; Educational Grants: Bayer, Roche; Advisory Board: Bayer, Boehringer Ingelheim, Genentech, Inc., Novartis, Roche; Research Funding: Bayer. SRdS: Consultancy: AbbVie, Bayer, Roche; Travel Support: Bayer, Roche. RPG: AbbVie, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, Ocular Therapeutix, Roche, Santan. SS: Funding\/Fees: AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, EyeBio, EyePoint, Janssen, Kriya, Novartis, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Roche, Sanofi, Stealth. Editorial role: Editor in Chief of Eye. DV: Advisory Board\/ Honoraria: AbbVie, Astellas,\u00a0Bayer, Outlook Therapeutics,\u00a0Roche, Teva; Educational Travel Grants: AbbVie, Alimera, Bayer, Roche; Clinical Trial PI: AbbVie,\u00a0Bayer, EyeBio,\u00a0Novartis, Roche. RR: Advisory Board\/Honoraria: Roche; Grant Support: Macular Society. CB: Advisory Board\/Honoraria\/Travel Support: Alimera, Apellis, Bayer, Boehringer Ingelheim, Janssen, Novartis, Roche. LD: Advisory Board\/Honoraria: Alimera, Allergan, Bayer, Biogen, Novartis, Roche; Travel Grants: Allergan, Bayer, Novartis. CK: Advisory Board\/Consulting\/Honoraria\/Travel Expenses: Alimera, Bayer, Boehringer Ingelheim, Roche. GCC, PD: Employee: Genentech, Inc. Stocks and options: Roche. MD: Employee: Medisoft Ltd. NJ: Employee: Roche Products Ltd. AD: Employee: F. Hoffmann-La Roche Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}